A group of researchers and experts from fields as wide-ranging as Alzheimer’s disease biology, mouse models, behavioral research, medical imaging and others at Indiana University School of Medicine have joined hands to investigate the efficacy of drugs used for the treatment of hitherto incurable Alzheimer’s disease. In a bid to benefit the Alzheimer’s research community, they have developed a research infrastructure after rigorously examining clinical characteristics, meticulously noting measurements of various depositions during treatment, and then making this data available for drug development. This research pipeline also gives an opportunity to independent researchers to submit compounds to be examined. The consortium is named Model Organism Development and Evaluation for Late-Onset Alzheimer’s Disease (MODEL-AD) and is funded by National Institute on Aging.
Read More from News-Medical.net
